GenderGP welcomes the latest guidance issued by the General Pharmaceutical Council (GPhC), which supports the notion that decisions around which medications patients should be taking should be doctor-led, rather than patient-led. Online pharmacies have traditionally adopted this method which enables the person visiting the site to self-diagnose and select the medication they believe is the correct one, before a consultation with a medical practitioner takes place.
The guidance published by the GPhC requires pharmacy owners to make sure that their website and the websites of companies they work with, are arranged in such a way that a person can no longer choose a prescription-only medicine and its quantity before there has been an appropriate consultation with a prescriber. This reflects what is set out in the MHRA’s Blue Guide on the advertising and promotion of medicines.
As a digital provider of medicine, GenderGP has always operated according to a medically-led model of care, ensuring medical decisions are made by those with the necessary medical expertise. We believe this approach is safest in ensuring the best possible outcomes for all patients.
The latest update from the GPhC will provide an additional layer of protection for consumers in order to mitigate the risk of online prescribing services ‘prescribing medicines which are liable to abuse, misuse and overuse to people, on the basis of an online questionnaire.’
The communication also refers to ‘registered pharmacies dispensing prescription-only medicines from prescribers based in the EEA working alone or for third-party online prescribing services.’
As GenderGP works with prescribers based in the EEA we wanted to provide some clarity, to alleviate any confusion or concerns that might arise among pharmacists dispensing for our patents, following this statement.
It is important to note that there is a shortage of specialists working in the field of gender care. This field has, over recent years, become highly politicised in the UK resulting in some doctors even being reported to the regulator for their work supporting trans people.
As a result UK doctors are often reluctant to openly support this patent cohort who subsequently end up having to wait years to access the help they need. GenderGP therefore partners with medical professionals from Europe and further a-field who are selected because of their progressive and dedicated approach to supporting gender variant individuals.
GenderGP has been actively working with the General Pharmaceutical Council and the Royal Pharmaceutical Society to improve education and confidence for pharmacies dispensing for trans patients and we continue to strive to deliver only the very best service to our community in collaboration with our stakeholders.